Sophont develops multimodal medical foundation models trained on large amounts of unlabeled clinical data to reason across diverse modalities such as pathology slides, brain scans, clinical notes, and lab results. The company is positioning itself as a medical AI infrastructure provider and plans to release state-of-the-art model backbones later this year to enable med-tech companies and pharmaceutical R&D teams to fine-tune models. Initial use cases mentioned include symptom triage, biomarker discovery, and patient selection for clinical trials. Sophont was built in partnership with academics, clinicians, and the broader machine learning community and publishes open-source medical AI research in venues including Nature Biomedical Engineering, NeurIPS, and ICML. Founders include CEO Tanishq Abraham and CTO Paul Scotti, who bring prior roles at Stability AI and academic experience. The company says it will use the new funding to expand its research team, accelerate model development, and launch pilot programs with healthcare institutions, healthtech companies, and pharmaceutical companies.

Total raised

$9M

Funding rounds

1

Latest round

Seed

Latest activity

Sep 2025